MFS Research International Fund
MFS SERIES TRUST I · Series S000000766 · 9 share classes
data updated 2026-09-08
Fund profile
As filed in the prospectus · 2025 Q4
The funds investment objective is to seek capital appreciation.
The fund invests primarily in foreign equity securities across developed and emerging markets, selected through bottom-up fundamental analysis by a team of sector leaders and research analysts; it may also use quantitative screening tools to evaluate issuers. The fund is managed to be sector neutral to the MSCI EAFE Index using the adviser's custom industry and sector classifications. Because the fund's active selection approach may diverge from the index's holdings, performance may differ from the MSCI EAFE Index.
| Share class | Gross | Net |
|---|---|---|
| MRSAX | 1.00% | 0.99% |
| MRSJX | 0.75% | 0.74% |
| MRIBX | 1.75% | 1.74% |
| MRICX | 1.75% | 1.74% |
| MRSIX | 0.75% | 0.74% |
| MRSGX | 1.75% | 1.74% |
| MRSRX | 1.25% | 1.24% |
| MRSHX | 1.00% | 0.99% |
| MRSKX | 0.65% | 0.64% |
Net is what a holder pays after the adviser's contractual waiver; gross is before it. A waiver can expire.
Portfolio turnover 27.00% · as of 2025 Q4
Allocation
Asset groups · long / short shown separately, never netted · 2026 Q2
| Stocks | 99.72% |
| Cash & short-term | 1.55% |
| Other | 0.01% |
Derivatives are shown at market value, not notional exposure.
Latest quarter
What changed since the fund's previous filing
Largest new: AstraZeneca PLC, JP Morgan US Government Money Market Fund, Roche Holding AG, Deutsche Boerse AG, Aker BP ASA, CVC Capital Partners PLC, Renesas Electronics Corp, POUND STERLING
Exited: Roche Holding AG, Euronext NV, Galp Energia SGPS SA, Capcom Co Ltd, SOUTH KOREAN WON
Return profile
Total return as filed — price change plus distributions reinvested · trailing figures to Apr 2026
| Share class | 1-year | 3-year | 5-year | Vol | Worst fall |
|---|---|---|---|---|---|
| +20.37% | +37.34% | +32.69% | 14.30% | -10.29% | |
| +20.67% | +38.34% | +34.39% | 14.35% | -10.21% | |
| +19.45% | +34.29% | +27.82% | 14.30% | -10.44% | |
| +19.49% | +34.36% | +27.83% | 14.29% | -10.44% | |
| +20.64% | +38.40% | +34.42% | 14.29% | -10.24% | |
| +19.44% | +34.17% | +27.68% | 14.32% | -10.53% | |
| +20.06% | +36.34% | +31.06% | 14.29% | -10.34% | |
| +20.37% | +37.36% | +32.71% | 14.33% | -10.31% | |
| +20.80% | +38.86% | +35.05% | 14.34% | -10.20% |
These classes hold the same portfolio, so the 7.37pp spread over 5 years is the cost difference between them — roughly 1.47pp a year — not a difference in what they own.
May 2026 has been filed since the trailing figures were struck, so it is not in the table above or the curve — every figure here shares one cut-off, which is what makes them comparable with other funds.
Holdings
By % of NAV · equity positions carry filed share counts · every resolvable issuer links to its company page
| Ticker | Issuer | %NAV | Reported price | Value | Shares |
|---|---|---|---|---|---|
| — | Mizuho Financial Group Inc | 2.90% | $45.18 | $514.19M | 11.4M |
| — | Schneider Electric SE | 2.82% | $314.87 | $500.71M | 1.6M |
| — | Hitachi Ltd | 2.45% | $32.44 | $434.42M | 13.4M |
| — | ASML Holding NV | 2.21% | $1,615.23 | $393.22M | 243.4K |
| — | Taiwan Semiconductor Manufacturing Co Ltd | 2.21% | $75.18 | $391.85M | 5.2M |
| — | Novartis AG | 2.12% | $150.94 | $375.78M | 2.5M |
| — | TotalEnergies SE | 2.10% | $87.69 | $372.87M | 4.3M |
| — | Tokyo Electron Ltd | 1.90% | $329.14 | $336.77M | 1.0M |
| — | AstraZeneca PLC | 1.78% | $185.87 | $316.31M | 1.7M |
| — | Linde PLC | 1.76% | $497.69 | $312.73M | 628.4K |
Reported price is the fund's own reported value divided by its own reported shares at 2026-05-31 — not a live quote, and not what the fund paid.
Top 10 positions are 22.23% of net assets, top 25 43.30%, across 121 issuers.
See more of this fund's book
More positions with filed share counts, and the quarter-over-quarter change list rather than the largest few — free with an account, no card required.
Sign in free